Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
151.920
Open
149.300
VWAP
149.79
Vol
2.77M
Mkt Cap
12.50B
Low
145.610
Amount
414.54M
EV/EBITDA(TTM)
8.91
Total Shares
82.78M
EV
15.21B
EV/OCF(TTM)
11.82
P/S(TTM)
1.50
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
2.07B
+1.79%
3.553
+6.06%
2.05B
-3.46%
3.363
-10.33%
2.01B
-3.9%
3.211
-7.46%
Estimates Revision
The market is revising Downward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by -1.92% over the past three months. During the same period, the stock price has changed by -22.54%.
Revenue Estimates for FY2025
Revise Downward
-1.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-4.23%
In Past 3 Month
Stock Price
Go Down
-22.54%
In Past 3 Month
14 Analyst Rating
41.16% Upside
Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 213.77 USD with a low forecast of 157.00 USD and a high forecast of 265.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy
41.16% Upside
Current: 151.440
Low
157.00
Averages
213.77
High
265.00
41.16% Upside
Current: 151.440
Low
157.00
Averages
213.77
High
265.00
JP Morgan
Casey Woodring
Buy
to
Hold
Downgrades
$265 → $150
2025-04-29
New
Reason
JP Morgan
Casey Woodring
Price Target
$265 → $150
2025-04-29
New
Downgrades
Buy
to
Hold
Reason
JPMorgan downgraded Icon to Neutral from Overweight with a price target of $150, down from $265. The firm cites limited visibility in near-term end market improvement heading into Q1 earnings for the downgrade. Results from JPMorgan's recent clinical contract research organization survey point to a more uncertain forward looking market backdrop in both large pharma and Smid-cap biotech, with 67% of large pharma respondents and 80% SMID biotech respondents indicating that their budgets are either "somewhat likely" or "very likely" to see cuts over the next 6-12 months, the analyst tells investors in a research note. JPMorgan adds that intra-quarter headlines around the choppy macro environment, pharma tariffs, volatile biotech funding and turnover at the FDA "have also driven caution on the set-up for the rest of the year."
TD Cowen
Charles Rhyee
Strong Buy
to
Hold
Downgrades
$254 → $157
2025-04-14
Reason
TD Cowen
Charles Rhyee
Price Target
$254 → $157
2025-04-14
Downgrades
Strong Buy
to
Hold
Reason
TD Cowen downgraded Icon to Hold from Buy with a price target of $157, down from $254. The firm entered 2025 "more optimistically," thinking a rebound in demand in the second half of 2025 would occur as biopharma reprioritizations come to an end, leading to accelerating growth in 2026 off historical trough multiples for Icon. However, TD's channel checks have since dissuaded it of that notion. The analyst's analysis suggests that the ongoing shift to functional service provision is likely to affect Icon the most in 2025 and 2026.
Barclays
Luke Sergott
Buy
to
Hold
Downgrades
$240 → $165
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$240 → $165
2025-04-10
Downgrades
Buy
to
Hold
Reason
Barclays downgraded Icon to Equal Weight from Overweight with a price target of $165, down from $240. The firm moved to the sidelines on the contract research organizations, citing lower confidence around pharma restructurings based on the pharma-specific tariff overhang. The firm considers the potential reaction of further cost-cutting and budget rightsizing from the "looming pharma-specific tariffs yet to be announced." Pharma can not pass on the tariffs via increased drug pricing, as the Inflation Reduction Act caps Part D price increases at inflation, the analyst tells investors in a research note.
Truist Securities
Jailendra Singh
Strong Buy
Maintains
$262 → $208
2025-04-10
Reason
Truist Securities
Jailendra Singh
Price Target
$262 → $208
2025-04-10
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Icon to $208 from $262 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results for Contract Research Organizations, or CROs. The firm is lowering its estimates and price targets for to reflect recent trends and macro uncertainty. Truist states it had previously believed that large pharma market was already halfway through with respect to portfolio reprioritization, but given the funding trends of the past two months and the uncertain pharma industry environment in general, its baseline assumption now sees biotech recovery being pushed out to at least the second half of 2025 and the large pharma market recovery to the first half of 2026, the analyst tells investors in a research note.
Mizuho
Ann Hynes
Buy
Maintains
$238 → $200
2025-04-09
Reason
Mizuho
Ann Hynes
Price Target
$238 → $200
2025-04-09
Maintains
Buy
Reason
Mizuho analyst Ann Hynes lowered the firm's price target on Icon to $200 from $238 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
Citigroup
Patrick Donnelly
Strong Buy
Maintains
$290 → $215
2025-04-07
Reason
Citigroup
Patrick Donnelly
Price Target
$290 → $215
2025-04-07
Maintains
Strong Buy
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Icon to $215 from $290 and keeps a Buy rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector.
See All Ratings
Valuation Metrics
The current forward P/E ratio for ICON PLC (ICLR.O) is 11.12, compared to its 5-year average forward P/E of 19.83. For a more detailed relative valuation and DCF analysis to assess ICON PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Undervalued
5Y Average PE
19.83
Current PE
11.12
Overvalued PE
23.70
Undervalued PE
15.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
14.54
Current EV/EBITDA
9.22
Overvalued EV/EBITDA
17.41
Undervalued EV/EBITDA
11.67
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
2.49
Current PS
1.46
Overvalued PS
3.01
Undervalued PS
1.98
Financials
Annual
Quarterly
FY2024Q4
YoY :
-1.22%
2.04B
Total Revenue
FY2024Q4
YoY :
+27.63%
351.27M
Operating Profit
FY2024Q4
YoY :
+20.14%
260.00M
Net Income after Tax
FY2024Q4
YoY :
+20.61%
3.16
EPS - Diluted
FY2024Q4
YoY :
-28.49%
277.03M
Free Cash Flow
FY2024Q4
YoY :
+8.12%
24.63
Gross Profit Margin - %
FY2024Q4
YoY :
+7.48%
13.51
FCF Margin - %
FY2024Q4
YoY :
+21.68%
12.74
Net Margin - %
FY2024Q4
YoY :
+7.78%
7.76
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 722.73% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
185.2K
Volume
3
6-9
Months
0.0
Volume
0
0-12
Months
512.4K
Volume
14
Bought
0-3
0
0.0
Volume
Months
3-6
17
2.9M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
10
350.8K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
8.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ICLR News & Events
Events Timeline
2025-04-30 (ET)
2025-04-30
16:28:52
Icon now sees FY adjusted EPS $12.75-$14.25, consensus $13.62
2025-04-30
16:28:00
Icon reports Q1 adjusted EPS $3.19, consensus $3.10
2025-03-04 (ET)
2025-03-04
09:07:17
Icon adopting Mural Health's participant management and payments platform
Sign Up For More Events
Sign Up For More Events
News
4.0
04-29BenzingaThis Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
4.0
04-14BenzingaTD Cowen Downgrades Icon to Hold, Lowers Price Target to $157
7.0
04-11GlobenewswireICLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Sign Up For More News
People Also Watch
KRNY
Kearny Financial Corp
6.260
USD
-0.63%
CLCO
Cool Company Ltd
6.350
USD
+3.59%
PHAT
Phathom Pharmaceuticals Inc
4.290
USD
-1.61%
SNDL
SNDL Inc
1.490
USD
+0.68%
RICK
RCI Hospitality Holdings Inc
39.680
USD
-3.05%
TRDA
Entrada Therapeutics Inc
9.130
USD
+2.13%
BOC
Boston Omaha Corp
15.530
USD
-0.70%
BLDP
Ballard Power Systems Inc
1.220
USD
-0.81%
GBLI
Global Indemnity Group LLC
28.860
USD
-0.35%
GFR
Greenfire Resources Ltd
4.660
USD
-1.27%
FAQ
What is ICON PLC (ICLR) stock price today?
The current price of ICLR is 151.44 USD — it has increased 1.43 % in the last trading day.
What is ICON PLC (ICLR)'s business?
What is the price predicton of ICLR Stock?
What is ICON PLC (ICLR)'s revenue for the last quarter?
What is ICON PLC (ICLR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ICON PLC (ICLR)'s fundamentals?
How many employees does ICON PLC (ICLR). have?